Gamolenic acid - Scotia Pharmaceuticals

Drug Profile

Gamolenic acid - Scotia Pharmaceuticals

Alternative Names: Efamast; Efarmol; Epogam; Epogam Snip-Off capsules; Epostart; Gamma linolenic acid; Gamolenic acid/vitamin E; Primast; Primogam

Latest Information Update: 03 Oct 2011

Price : $50

At a glance

  • Originator Scotia Holdings [CEASED]; Scotia Pharmaceuticals [CEASED]
  • Class Small molecules; Unsaturated fatty acids
  • Mechanism of Action Cell adhesion molecule inhibitors; Immunomodulators; Prostaglandin synthase stimulants; Thromboxane synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis
  • Market Withdrawal Breast pain
  • Discontinued Breast cancer; Rheumatoid arthritis

Most Recent Events

  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 07 Oct 2002 Withdrawn for Atopic dermatitis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top